31^st Annual Congress on Vaccines, Clinical Trials & B2B July 27-28, 2018 Vancouver, Canada

Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Clinical and laboratory applied, Virology basic and diagnostic, Viral Oncology, Immunology clinical practice,Vaccines.

Francis Eko is professor of Microbiology and Immunology at Morehouse School of Medicine, Atlanta (USA). His expertise is in design and development of self-adjuvanting, cold-chain free vaccines and vaccine adjuvants. Current research involves investigation of the mechanisms of Chlamydia infection- and vaccine-induced immunity and the effect of VCG-based adjuvants on immunity to mucosal and systemic vaccines.

Vaccines

Clayton Dehn is a clinical research physiologist with particular expertise in Proof-of-Concept testing methods. He is a co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders by selectively disabling genetically undesirable sperm cells. He is also the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. Clayton brings over 15 years of knowledge and international experience as a clinical research professional in the drug development industry.

Clinical Research